NCT05479474 Platelet Rich Plasma Testis Treatment for Infertile Men
| NCT ID | NCT05479474 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Male Infertility |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2023-01-18 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2023-01-18 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Investigate the effect of intratesticular injection of autologous platelet rich plasma (PRP) on sperm retrieval rates and IVF outcomes in infertile men who already underwent a negative sperm retrieval. Currently, there is no alternative treatment after failed TESE. Prior series suggest that intratesticular PRP injections may improve TESE outcomes. We hope to determine whether PRP is an effective treatment for this patient population.
Eligibility Criteria
Inclusion Criteria: * Men over the age of 18 diagnosed with NOA and at least one failed TESE, negative mapping or negative biopsy Exclusion Criteria: \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05479474 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Male Infertility. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05479474 currently recruiting?
Yes, NCT05479474 is actively recruiting participants. Contact the research team at sbasran@stanford.edu for enrollment information.
Where is the NCT05479474 trial being conducted?
This trial is being conducted at Stanford, United States.
Who is sponsoring the NCT05479474 clinical trial?
NCT05479474 is sponsored by Stanford University. The trial plans to enroll 10 participants.